Table 2.
Author | Year | Patients (N) | Technique | CTV | Dose | Marginal Failure | PFS (%) | OS (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3-y | 5-y | 6-y | 8-y | 10-y | 3-y | 5-y | 6-y | 8-y | 10-y | |||||||
Saran et al. [13] | 2002 | 14 | SRT | GTV + 0.3–1.0 cm | 50–55 Gy | 0 | 87 | 100 | ||||||||
Marcus et al. [12] | 2005 | 50 | SRT | GTV | 50–58 Gy | 0 | 82.5 | 68 | 97.8 | 82 | ||||||
Merchant et al. [11] | 2009 | 78 | 3D-CRT/IMRT | GTV + 1.0 cm | 54 Gy | 1 | 87 | 74 | 98 | 96 | ||||||
Greenberger et al. [15] | 2014 | 32 | Proton | GTV + 0.3 cm | 52.2 RBE | 90 | 83 | 100 | 100 | |||||||
Paulino et al. [14] | 2013 | 39 | IMRT | GTV + 0.5–1.0 cm | 50.4 Gy | 0 | 78 | 94 | ||||||||
Current study | 2017 | 85 | 3D-CRT/IMRT | GTV + 0.5 cm | 54 Gy | 0 | 77 | 71 | 94 | 93 |
Abbreviations: CTV, clinical target volume; 3D-CRT, three-dimensional conformal radiation therapy; GTV, gross target volume; IMRT, intensity-modulated radiation therapy; OS, overall survival; PFS, progression-free survival; RBE, relative biological effectiveness; SRT, stereotactic radiation therapy